Medicare RWE negotiations represent an improved approach to drug pricing under the 2022 Inflation Reduction Act, as Medicare now negotiates prices for high-cost, single-source drugs without generic or biosimilar rivals that account for major Part D spending. The initial 10 prices, starting January 2026, cut costs by 8% to 42% from 2021 baselines (JAMA, doi:10.1001/jama.2025.21498). This update outlines how real-world evidence (RWE) informs these processes and provides healthcare leaders and policymakers with practical strategies to enhance value alignment.
Historical Shift in US Drug Pricing
The Inflation Reduction Act grants Medicare unprecedented bargaining power, with negotiations targeting drugs late in their lifecycle unlike the swift processes in the UK or Germany where competitors evolve, off-label uses expand, and trials often underrepresent older adults. CMS guidance from September 2025 highlights RWE from claims and electronic health records, which helps evaluate health value against alternatives, as seen when CMS cited RWE in first-round justifications. Medicare RWE negotiations thus fill critical gaps as the third cycle launches in February 2026, covering Part B drugs.
Core Benefits of RWE in Practice
RWE delivers advantages that trials cannot match, since patients use drugs on- and off-label in real settings, including Medicare groups. Studies often reveal long-term impacts, for example, on cardiac events, dementia, or hospital admissions—outcomes trials rarely track. Consider semaglutide, where RWE shows glucagon-like peptide 1 effects beyond original endpoints, and moreover, RWE quantifies cost savings from fewer hospital stays or non-drug expenses, with these insights directly influencing prices and rewarding drugs that reduce overall burdens.
Designing Studies for Medicare RWE Negotiations
Effective studies align with CMS priorities, so first, researchers select comparators thoughtfully with CMS defining therapeutic alternatives per drug and indication, while descriptive data on clinical practices strengthens choices. Second, focus on statutory metrics by avoiding quality-adjusted life-years, and third, embrace off-label evidence where RCTs fall short through target trial emulation that ensures credibility. Researchers specify eligibility, assignment, and outcomes transparently, with covariates controlling confounding to enable causal claims, and fusion techniques blend trial and RWE data for outcomes like mortality. Triangulate findings across sources—academics, ICER, or contract firms—for robustness, as CMS weighs peer review and bias risks highly.
| Study Element | Best Practice | Impact on Negotiations |
|---|---|---|
| Comparators | Rationale with usage data | Accurate alternatives |
| Outcomes | Life-years, ADLs | Statute-compliant value |
| Methods | Target emulation | Low bias, causal insight |
Actionable Steps for Leaders
Researchers should prioritise transparent methods and timely outputs, while CMS can standardise submissions, pharma teams invest in RWE early, and all parties collaborate on data infrastructure like PCORI expansions. These steps ensure Medicare RWE negotiations deliver equitable, evidence-based results.
Summing Up the Value Proposition
Medicare RWE negotiations bridge trial limitations with real-world insights, promoting spending that matches outcomes, so leaders must act swiftly for upcoming cycles. Share your views – how will you apply RWE in pricing strategies?
Table of Contents
